Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Long-Term Deferred Tax: 2021-2024

Historic Long-Term Deferred Tax for Ironwood Pharmaceuticals (IRWD) over the last 4 years, with Dec 2024 value amounting to $144.2 million.

  • Ironwood Pharmaceuticals' Long-Term Deferred Tax fell 45.13% to $101.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.7 million, marking a year-over-year decrease of 45.13%. This contributed to the annual value of $144.2 million for FY2024, which is 32.07% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Long-Term Deferred Tax of $144.2 million as of FY2024, which was down 32.07% from $212.3 million recorded in FY2023.
  • Ironwood Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $333.3 million during FY2021, with a 5-year trough of $144.2 million in FY2024.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $212.3 million (2023), whereas its average is $213.4 million.
  • Data for Ironwood Pharmaceuticals' Long-Term Deferred Tax shows a maximum YoY crashed of 32.07% (in 2024) over the last 5 years.
  • Over the past 4 years, Ironwood Pharmaceuticals' Long-Term Deferred Tax (Yearly) stood at $333.3 million in 2021, then fell by 14.89% to $283.7 million in 2022, then fell by 25.15% to $212.3 million in 2023, then plummeted by 32.07% to $144.2 million in 2024.